Pnd99 - Cystic Fibrosis Therapies - Key Drivers Behind Differing Hta Decisions

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2065
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Inhaled Therapies, Azithromycin andMycobacterium Abscessusin Cystic Fibrosis Patients

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2012English

Reproductive Decisions After Neonatal Screening Identifies Cystic Fibrosis

Archives of Disease in Childhood: Fetal and Neonatal Edition
PediatricsGynecologyPerinatologyObstetricsMedicineChild Health
2000English

Antiinflammatory Therapies for Cystic Fibrosis: Past, Present, and Future

Pharmacotherapy
Pharmacology
2005English

Php223 - Trerapeutic Areas, a Key Factor for Hta and Reimbursement Decisions, Timming and Access

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

A G542X Cystic Fibrosis Mouse Model for Examining Nonsense Mutation Directed Therapies

PLoS ONE
Multidisciplinary
2018English

Cystic Fibrosis. 7. Management of Cystic Fibrosis in Different Countries. Cystic Fibrosis in Melbourne.

Thorax
PulmonaryRespiratory Medicine
1991English

Cystic Fibrosis. 7. Management of Cystic Fibrosis in Different Countries. Cystic Fibrosis in Copenhagen.

Thorax
PulmonaryRespiratory Medicine
1991English

Cystic Fibrosis.

Archives of Disease in Childhood
Child HealthPediatricsPerinatology
1990English

Cystic Fibrosis

Postgraduate Medical Journal
Medicine
1997English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy